Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study - 11/10/18
, G. Lebreton a, C. Bazille b, M.P. Galais c, B. Dupont f, A. Alves a, e, J. Lubrano a, e, R. Morello d, B. Menahem a, eBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Objective |
To evaluate long-term (5- and 10-year) survival and recurrence rates on the basis of the pathological complete response (pCR) in the specimens of patients with esophageal carcinoma, treated with trimodality therapy.
Methods |
Between 1993 and 2014, all consecutives patients with esophageal locally-advanced non-metastatic squamous cell carcinoma (SCC) or adenocarcinoma (ADC) who received trimodality therapy were reviewed. According to histopathological analysis, patients were divided in two groups with pCR and with pathological residual tumor (pRT). The primary endpoint was overall survival (OS). The secondary endpoints included the disease-free survival (DFS), the recurrence rate, and the predictive factors of overall survival and recurrence.
Results |
One hundred and three patients were included: 49 patients with pCR and 54 patients with pRT. The median OS was significantly longer in pCR group than in pRT group (132±22.3 vs. 25.5±4 months), with both 5- and 10-years OS rates of 75.2% vs. 29.1%, and 51.1% vs. 13.6%, respectively (P<0.001). Also, pRT, major postoperative complications (Dindo-Clavien grade>IIIb) and recurrence were the 3 independent predictive factors for worse OS.
Conclusions |
Patients with locally-advanced oesophageal carcinoma, who responded to trimodality therapy with a pCR, could be achieved a 10-year survival rate of 51%.
Le texte complet de cet article est disponible en PDF.Keywords : Esophageal cancer, Neoadjuvant chemoradiotherapy, Pathological complete response, Survival, Recurrence
Plan
Vol 155 - N° 5
P. 365-374 - octobre 2018 Retour au numéro
Article précédent
- Mid-term outcomes after biologic mesh use: Does their performance meet our expectations?
- P. Brinas, M. Chalret du Rieu, G. Tuyeras, C.H. Julio, S. Kirzin, L. Ghouti, N. Carrere
- Use of routine CT-SCANS to detect severe postoperative complications after pancreato-duodenectomy
- E. Cuellar, F. Muscari, G. Tuyeras, C. Maulat, B. Charrière, J.-P. Duffas, P. Otal, B. Bournet, B. Suc
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?